On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...

US FDA approves Novartis' kidney disease drug. By Sriparna Roy. August 7, 2024 10:29 PM UTC Updated August 7, 2024. The logo of Swiss drugmaker Novartis is pictured at the ...

The approval Vanrafia marks the third drug approval for Novartis in its renal disease portfolio. Shares of Novartis have risen 16.5% year to date compared with the large cap pharmaceutical ...

A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval, strengthening the product’s case to compete against two other ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication ... FDA Approves Novartis Drug for Rare Kidney Disease Treatment March 21, 2025 — 02:10 pm EDT.

C3G is a rare kidney disease characterized by damage to the glomeruli ... On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) oral Fabhalta ...